Worldquant Millennium Advisors LLC Buys New Position in Charles River Laboratories International, Inc. (NYSE:CRL)

Worldquant Millennium Advisors LLC bought a new stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 132,426 shares of the medical research company’s stock, valued at approximately $24,446,000. Worldquant Millennium Advisors LLC owned approximately 0.26% of Charles River Laboratories International at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in CRL. D1 Capital Partners L.P. bought a new stake in shares of Charles River Laboratories International during the 4th quarter valued at about $172,752,000. Norges Bank bought a new position in Charles River Laboratories International in the fourth quarter worth approximately $98,886,000. Wellington Management Group LLP boosted its holdings in Charles River Laboratories International by 9.0% in the fourth quarter. Wellington Management Group LLP now owns 4,076,426 shares of the medical research company’s stock worth $752,508,000 after acquiring an additional 335,658 shares in the last quarter. Nomura Holdings Inc. bought a new position in Charles River Laboratories International in the fourth quarter worth approximately $56,820,000. Finally, Raymond James Financial Inc. bought a new position in Charles River Laboratories International in the fourth quarter worth approximately $42,776,000. Institutional investors own 98.91% of the company’s stock.

Insider Activity at Charles River Laboratories International

In other Charles River Laboratories International news, COO Birgit Girshick purchased 1,514 shares of the firm’s stock in a transaction that occurred on Thursday, February 20th. The stock was bought at an average cost of $164.63 per share, with a total value of $249,249.82. Following the completion of the transaction, the chief operating officer now owns 55,058 shares of the company’s stock, valued at $9,064,198.54. The trade was a 2.83% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Joseph W. Laplume sold 500 shares of the stock in a transaction on Tuesday, May 13th. The shares were sold at an average price of $145.41, for a total value of $72,705.00. Following the transaction, the executive vice president now directly owns 19,513 shares of the company’s stock, valued at approximately $2,837,385.33. This trade represents a 2.50% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 5,040 shares of company stock valued at $807,407. 1.30% of the stock is owned by insiders.

Wall Street Analyst Weigh In

Several brokerages have issued reports on CRL. William Blair lowered Charles River Laboratories International from an “outperform” rating to a “market perform” rating in a report on Wednesday, January 22nd. Barclays increased their price target on Charles River Laboratories International from $145.00 to $155.00 and gave the stock an “equal weight” rating in a report on Thursday, May 8th. TD Cowen upgraded Charles River Laboratories International from a “hold” rating to a “buy” rating and set a $179.00 price target on the stock in a report on Wednesday, May 14th. Evercore ISI upgraded Charles River Laboratories International from an “in-line” rating to an “outperform” rating and set a $170.00 price target on the stock in a report on Thursday, May 8th. Finally, Mizuho cut their price target on Charles River Laboratories International from $175.00 to $155.00 and set a “neutral” rating on the stock in a report on Wednesday, April 9th. One investment analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat.com, Charles River Laboratories International presently has an average rating of “Hold” and a consensus target price of $172.31.

Charles River Laboratories International Stock Performance

Shares of CRL opened at $143.49 on Wednesday. The company has a current ratio of 1.41, a quick ratio of 1.14 and a debt-to-equity ratio of 0.65. The company has a market capitalization of $7.05 billion, a price-to-earnings ratio of 956.60, a PEG ratio of 4.54 and a beta of 1.50. The stock has a 50 day moving average of $134.37 and a 200 day moving average of $164.34. Charles River Laboratories International, Inc. has a 12 month low of $91.86 and a 12 month high of $254.15.

Charles River Laboratories International (NYSE:CRL) last issued its quarterly earnings results on Wednesday, May 7th. The medical research company reported $2.34 EPS for the quarter, beating analysts’ consensus estimates of $2.06 by $0.28. The company had revenue of $984.17 million during the quarter, compared to the consensus estimate of $942.34 million. Charles River Laboratories International had a return on equity of 14.69% and a net margin of 0.52%. Charles River Laboratories International’s revenue was down 2.7% on a year-over-year basis. During the same period last year, the business posted $2.27 earnings per share. As a group, sell-side analysts forecast that Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current year.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).